Hansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation
28 Nov 2022, 18:00 Regulatory information
"Hansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation"
https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-announces-positive-topline-data-from-the-imlifidase-phase-2-study-in-antibody-mediated-rejection-amr-episodes-post-kidney-transplantation/
28 Nov 2022, 18:00 Regulatory information
"Hansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation"
https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-announces-positive-topline-data-from-the-imlifidase-phase-2-study-in-antibody-mediated-rejection-amr-episodes-post-kidney-transplantation/
